Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 19;9(6):675.
doi: 10.3390/vaccines9060675.

Evaluation of SARS-CoV-2 Spike Protein Antibody Titers in Cord Blood after COVID-19 Vaccination during Pregnancy in Polish Healthcare Workers: Preliminary Results

Wojciech Zdanowski  1   2 , Tomasz Waśniewski  1   2
Affiliations

Evaluation of SARS-CoV-2 Spike Protein Antibody Titers in Cord Blood after COVID-19 Vaccination during Pregnancy in Polish Healthcare Workers: Preliminary Results

Wojciech Zdanowski et al. Vaccines (Basel). .

Abstract

Background: The coronavirus disease 2019 (COVID-19) pandemic has given rise to the need to develop a vaccine as quickly as possible. As pregnant women are at increased risk of contracting severe COVID-19, with higher mortality, it is essential to assess the safety of the vaccines administered during pregnancy.

Methods: The aim of this study was to determine the titer of specific maternal and cord antibodies against severe acute respiratory syndrome coronavirus 2 S protein after antenatal vaccination. The secondary objective was to evaluate the ratio of the umbilical cord to the maternal antibody titers. Patients included in the study were enrolled after undergoing voluntary vaccination against COVID-19 during pregnancy at different weeks of gestation. All patients analyzed in our initial study were vaccinated with the BNT162b2 mRNA COVID-19 vaccine.

Results: The results of the current study document high anti-S total IgG antibody titers in cord serum at birth in all mother-infant pairs analyzed. The mean umbilical cord blood sample IgG antibody titer anti-S protein was 1026.51 U/mL (±SD 769.25). The mean cord-to-maternal anti-S IgG antibody ratio was 1.28 (±SD 0.798). A significant positive correlation was observed between the week of gestation at which the first dose was administered and the week of gestation at which the second dose was administered, and the respective cord-to-maternal ratio (r = 0.48; p = 0.0029) for the first dose and (r = 0.39; p = 0.0102) for the second dose.

Conclusions: To date, despite the prevalence of COVID-19 vaccination, there is a lack of conclusive evidence supporting the safety and efficacy of vaccination of pregnant women. Therefore, the results we present are complementary. Our study suggests that maternal immunization may provide neonatal protection through the transplacental transfer of antibodies. Of particular importance is the demonstration that antibody transfer is correlated with the time from vaccination to delivery, which may allow future determination of the optimal timing of COVID-19 vaccination in pregnant women.

Keywords: COVID-19; pregnancy; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflict of interest.

Figures

Figure 1
Figure 1
Mean time (weeks) from the first and the second dose of vaccine to delivery.
Figure 2
Figure 2
Mean anti-S antibody titers in maternal and umbilical cord blood.
Figure 3
Figure 3
Correlation between the number of weeks from the first vaccine dose to delivery and the anti-S antibody titer in cord blood serum.
Figure 4
Figure 4
Correlation between the period (weeks) from the first vaccine dose to delivery and cord-to-maternal anti-S titer ratio.
Figure 5
Figure 5
Correlation between the period (weeks) from the second vaccine dose to delivery and cord-to-maternal anti-S titer ratio.
Figure 6
Figure 6
Correlation between the week of gestation when the first vaccine dose was administered and cord-to-maternal anti-S titer ratio.
Figure 7
Figure 7
Correlation between the week of gestation when the second vaccine dose was administered and cord-to-maternal anti-S titer ratio.
See this image and copyright information in PMC

References

    1. Masmejan S., Pomar L., Lepigeon K., Favre G., Baud D., Rieder W. COVID-19 et grossesse [COVID-19 and pregnancy] Rev. Med. Suisse. 2020;16:944–946. - PubMed
    1. Rasmussen S.A., Kelley C.F., Horton J.P., Jamieson D.J. Coronavirus disease 2019 (COVID-19) vaccines and pregnancy: What obstetricians need to know. Obstet. Gynecol. 2021;137:408–414. doi: 10.1097/AOG.0000000000004290. - DOI - PMC - PubMed
    1. European Medicines Agency Procedure No. EMEA/H/C/005735/0000. Assessment Report: COVID-19 mRNA Vaccine (Nucleoside-Modified) [(accessed on 6 April 2021)]; Available online: https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-....
    1. Stafford I.A., Parchem J.G., Sibai B.M. The coronavirus disease 2019 vaccine in pregnancy: Risks, benefits, and recommendations. Am. J. Obstet. Gynecol. 2021;224:484–495. doi: 10.1016/j.ajog.2021.01.022. - DOI - PMC - PubMed
    1. COVID-19 (Coronavirus Disease): People with Certain Medical Conditions. [(accessed on 6 April 2021)]; Available online: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-....